← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV23행 · 1개 프로그램
OverviewTechnologyMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
CD123 CAR-T cells (CD123 CAR-T cells)
Hebei Senlang Biotechnology Inc., …·Acute Myelocytic Leukemia
37 trials
Overview
Program
CD123 CAR-T cells
Overview
Company
Hebei Senlang Biotechnology Inc., Ltd.
Overview
Modality
CGT
Overview
Target
Acute Myelocytic Leukemia
Overview
Indication
Acute Myelocytic Leukemia
Overview
Phase
PHASE_1
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Technology
Vector
retroviral and lentiviral engineering CD28/4-1BB CD123 CAR T cells exhibit effector functi
MoA
Mechanism
Targeted Chimeric Antigen Receptor
MoA
Biomarker
CD19 CAR T-cells produce high
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse, In vitro
PK/PD
Experiment
PD
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse, In vitro
Toxicology
Major finding
hepatotoxicity - are characterized in detail, with attention to mitigation strategies
Toxicology
CRS
Reported
Clinical
Safety signal
hepatotoxicity - are characterized in detail, with attention to mitigation strategies
Clinical
Program phase
PHASE_1